National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Ceftazidime-avibactam (CEF-AVI)(Zavicefta®) is indicated for the treatment of CIAI, cUTI, HAP (including VAP) and gram negative infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.

 

Rapid Review

Commenced Completed Outcome
17/05/2017 13/06/2017 Full Pharmacoeconomic Evaluation Recommended at the Submitted Price

 

 

The HSE has approved reimbursement following confidential price negotiations November 2017.